Simple tests can diagnose cancer and its type. How does Freenome do it?
Release date: 2016-10-11 Freenome is an emerging liquid biopsy diagnostic biotechnology company in Philadelphia, USA, that diagnoses cancer by dynamic collection of genetic material in blood (free cells). Compared with traditional cancer detection, such as time-consuming detection methods such as slice diagnosis, it can also be used as a cancer detection system to provide early warning in the early stage of cancer, so as to take treatment as soon as possible. This year, Freenome also won a 5.55M venture capital fund from companies such as Andreessen Horowitz (hereinafter referred to as A16Z). The annual revenue is about $3.5 million and plans to push the test further to market. The conversion research that has been discovered has won the Verizon Powerful Answers Award In 2014, Gabriel Otte, CEO of research in academia, realized that new biological research is changing with each passing day, but there are very few that really make sense to patients. He believes that if diseases like cancer can be discovered early, many problems can be circumvented. He also believes that research or technology for treating diseases such as cancer has been achieved, but unfortunately no one has conducted in-depth applied research on these studies. So he and his partners Charlie Roberts and Riley Ennis co-founded Freenome. Charlie is a clinician who created DNA theory of free cells (free floating in the blood) based on a study of noninvasive early testing. Riley, through her own cancer immunotherapy company, has a deep research on cancer. Gabriel brings together knowledge of genomics and instrumental research and combines them to achieve non-invasive early detection. Focus on research that transforms existing findings into problem solutions, using biocompatibility, biophysics, cells and big data to design devices that can detect diseases in real time, providing innovative and effective solutions to help people avoid diseases. A healthier life. Freenome won the 2014 Verizon Powerful Answers Award and received a $700,000 award. Genomics + algorithm to achieve cancer warning Gabrie believes that cancer detection solutions need to create new algorithms in biological research. Modern DNA sequencing has answered many traditional biological problems. But sometimes, biology is far more complicated than technology. Most researchers focus on simplifying biological models that are less than 2% of DNA sequences. For the detection of some complex diseases, this is not enough. Freenome combines programs, instrument learning and computer biology to develop new computational methods and develop new and effective tools to solve clinical problems such as disease screening, diagnosis and treatment. Utilize the ability of next-generation sequencing to create personalized, non-invasive disease diagnosis and treatment for cancer and other diseases. "Our technology relies on deep integration of genomics research and algorithms." Gabrie: "But to understand it, first I want to explain what a freenome is." Freenome is the genetic material in the blood (free cells) of hundreds of millions of cells in the body. The dynamic collection of flows is the temporal and spatial variation of the living cell genome of the body. “By understanding one's freenome, we developed the ability to conduct early cancer testing,†Gabrie added. Dynamic genetic information is extracted from the blood by technical means. The algorithm is used to match the genetic information of the blood sample with the genetic information in the database, and finally the possibility of the bleeding host owner suffering from cancer can be obtained. Not only is the detection of cancer, the test can also be used as a detection system for human health, helping people make better health choices and achieve precise medical treatment. The adaptive learning engine matches the sample data with the data of free cell DNA to determine the probability of cancer. Over time, the engine can accumulate more data. In addition to improving the accuracy of the test, it is also possible to determine which type. Cancer The company focuses on developing new technology solutions to understand dynamic substances like freenome. A learning engine, also called Adaptive Genomics Engine (AGE), has been developed to analyze genetic health in one of the broadest and most comprehensive ways. Freenome's technology can help detect every possible sign of cancer and detect the location of a specific cancer, making the test more accurate, rather than focusing on a few mutations to establish a cancer test. In addition, the AGE learning library can also store the detected genetic information into its own knowledge base to further expand the data information. In other words, the more times the detection is performed, the more accurate and detailed the detection results are. Automatically classify the detected sample information storage, and then match the sample to be tested, and finally not only can detect disease/health, but also detect the location of cancer and the type of cancer. The learning engine analyzes and classifies each sample to calculate the probability of cancer and the type of cancer The advent of the era of genomics solves problems that cannot be solved by traditional biomedicine. We are programmers, machine learning experts, computational biologists, developing new computational methods, and developing new and effective tools to solve clinical problems such as disease screening, diagnosis and treatment. We leverage the capabilities of next-generation sequencing to create personalized, non-invasive disease diagnosis and cancer treatment, as well as other diseases. Open blind test, further close to clinical application The investment in A16Z not only brought in funds, but also led by the A16Z bio-fund partner Vijay Pande, bringing a unique blend of biology, technology and commerce. “From the moment I met Vijay and his colleague Malinka Walaliyadde, I knew how to properly build a company like Freenome,†Gabrie said. They understand that this space must be innovative, must be responsible, and work with regulators and academics. The A16Z team not only discussed the technology with Freenome, but also proposed a platform for open blind testing. “Although we know that our technology is not really mature, if we can't pass this test, then the clinical application of this technology will not make much sense. Freenome sent 5 unknown plasma samples. And the laboratory is required to classify. The laboratory will analyze the samples, not only distinguish cancer and health samples, but also find three cancers that may have cancer, stage I cancer, III cancer and IV. cancer. This also illustrates the prospects and possibilities of Freenome in clinical applications. Future goals: to provide more economical and accurate technology for cancer treatment Not only that, but Freenome also realized that just a single test is not enough and that proper treatment is needed. Freenome's technology is not about studying static genomes. The questions that can be answered are not just simple "diseases" or "non-diseases." By working with leading research institutions, Freenome is expanding its technology beyond detecting disease and providing more information, such as the type of tumor, that can help identify more effective treatments. Gabrie believes that over time, Freenome's technology will be more mature, more economical and accurate, and can treat cancer. Currently, Freenome is preparing to publish its first research results, and will continue to work with clinical organizations and continue to actively advance the work of CMS and FDA pre-sales review. About liquid biopsy As early as 1000 years ago, Arab doctor Abulcasis (1013-1017) invented biopsy technology. The advantage of biopsy is that doctors can judge the condition based on the histological structure of the lesion. With the deepening of cancer research, traditional tissue biopsy techniques have shown many limitations: 1. Tissue biopsy has hysteresis. 2. Tumors are specific. For patients whose cancer cells have metastasized, only taking a certain part of the tumor tissue does not reflect the overall situation, and sampling and testing of all tissues is unrealistic. 3. The condition of some patients determines that he is not suitable for tissue biopsy. As a branch of in vitro diagnosis, liquid biopsy solves the above problems and advances the diagnosis time of cancer. The advantage of liquid biopsy is not only the non-invasiveness of the test, but also the early detection and real-time monitoring of cancer, so as to prevent tumor recurrence. It can be used in early screening of cancer, dynamic monitoring of cancer patients and personalized medication guidance, and has broad market prospects. In addition to Freenome, there are hundreds of liquid biopsy companies in the United States, and seven excerpts have been selected here: Source: Arterial Network Wheeled Hose Reel Cart,Hose Cart With Wheels,Large Hose Reel Cart,Garden Hose Cart With Wheels NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.hosereelqikai.com
